新医学2017，Vol.48Issue(7)：495-498,4.DOI:10.3969/j.issn.0253-9802.2017.07.014
青年肺腺癌EGFR、KRAS基因突变与临床特点及预后的关系研究
Correlation between EGFR, KRAS gene mutations, clinical characteristics and prognosis of lung adenocarcinoma patients
朱晓丹 1陈成水2
作者信息
- 1. 322000 义乌,温州医科大学附属义乌医院呼吸内科
- 2. 325000 温州,温州医科大学附属第一医院呼吸内科
- 折叠
摘要
Abstract
Objective To investigate the relationship between the epidermal growth factor receptor (EGFR) and KRAS gene mutations and clinical characteristics and prognosis of young and middle-aged patients diagnosed with lung adenocarcinoma.Methods The expression of EGFR and KRAS genes in 168 lung adenocarcinoma patients aged 18 to 40 years was detected and relevant clinical data were collected.Clinical characteristics,therapeutic procedures and clinical prognosis between patients with mutant and wild-type EGFR and KRAS genes were statistically compared.Results Among 168 lung adenocarcinoma patients,74 (44.0%) were determined to have an EGFR mutation,and exon 19 and 21 mutation accounted for 90.5% (67/74).Among them,the proportion of the young female was 58.1%,and 73.0% for the non-smokers,significantly higher compared with 37.2% and 52.1% of their counterparts with wild-type EGFR (both P<0.01).The overall response rate (ORR) and progression-free survival (PFS) of EGFR mutation patients treated with EGFR inhibitor(EGFRI) were significantly higher than those of their counterparts receiving the first-line chemotherapy (both P<0.05).Eight patients (4.8%) were detected to have KRAS mutation at exon 2.Five cases received the first-line chemotherapy,and 3 treated with EGFRI.The ORR and PFS of 5 patients receiving EGFRI therapy were 2/3 and (8.4±5.7) months,and 2/5 and (6.4±3.6) months for their counterparts treated with the first-line chemotherapy.The ORR and PFS of EGFR mutant patients were significantly higher than those with wild-type EGFR (both P<0.05).No statistical significance was identified in terms of the prognosis between patients with mutant and wild-type KRAS (both P>0.05).Conclusions Young and middle-aged lung adenocarcinoma patients have a low risk of KRAS mutation,whereas a high risk of EGFR mutation.A majority of EGFR mutation patients are the female and non-smokers.EGFR mutant patients can obtain favorable clinical prognosis after EGFRI therapy.The clinical prognosis of EGFR mutant patients is better than that of those with wild-type EGFR.关键词
肺腺癌/表皮生长因子受体/KRAS/基因检测/预后Key words
Lung adenocarcinoma/Epidermal growth factor receptor/KRAS/Gene detection/Prognosis引用本文复制引用
朱晓丹,陈成水..青年肺腺癌EGFR、KRAS基因突变与临床特点及预后的关系研究[J].新医学,2017,48(7):495-498,4.
